Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform


Out of Business LATEST DEAL TYPE

Operator of a pharmaceutical company to develop trans-dermal product candidates for treating acute and chronic pain. The company' services focus on providing trans-dermal drugs by developing and applying novel technological advances for musculoskeletal disorders and peripheral neuropathy through biophysical modulation, enabling medical researchers to find an alternative to deliver and consume FDA-approved drugs for treating chronic pain resulting from musculoskeletal disorders and peripheral neuropathy.

Formerly Known As
Ownership Status
Out of Business
Financing Status
Formerly Angel backed
Primary Industry
Other Industries
Drug Delivery
Primary Office
  • 30 Washington Avenue
  • Suite F
  • Haddonfield, NJ 08033
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore inpellis’s full profile, request a free trial.

inpellis Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-May-2016 00.000 Completed Out of Business
1. Convertible Debt 01-Sep-2015 00.000 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

inpellis Executive Team (3)

Name Title Board
Patrick Mooney MD Chief Executive Officer & Board Member
David Staskin MD President, Secretary & Board Member
Frank Manguso Chief Financial Officer,Treasurer & Board Member

inpellis Board Members (7)

Name Representing Role Since Contact
David Staskin MD inpellis President, Secretary & Board Member 000 0000
Frank Manguso inpellis Chief Financial Officer,Treasurer & Board Member 000 0000
Frederic de Bure inpellis Board Member 000 0000
Galen Grayson MD inpellis Board Member 000 0000
Harry McCoy Ph.D inpellis Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »